Two stocks in Healthcare
Synektik Spółka Akcyjna vs UCB: profit, growth, debt and price compared
Synektik Spółka Akcyjna is stronger on 4 of 7 figures: profit margin, sales growth, debt and dividend. UCB is stronger on 2: price for its expected profit and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Synektik Spółka AkcyjnaSNT.WA | UCBUCB.BR | |
|---|---|---|
| Net margin | Stronger: 44.8% | 25.7% |
| Revenue growth, past year | Stronger: +89.50% | +22.50% |
| Debt to equity | Stronger: 19.4% | 30.8% |
| Forward P/E | 25.9× | Stronger: 18.7× |
| Dividend yield | Stronger: 3.40% | 0.51% |
| Analysts | Buy · 5 | Buy · 19 |
| From its 200-day average | −3.1% | Stronger: +17.2% |
Share price over the past year
- Synektik Spółka Akcyjna+10.1%
- UCB+17.6%
26 Nov 202520 Nov 2026
Synektik Spółka Akcyjna or UCB: which is stronger?
- SNT.WA
Which is more profitable?
Synektik Spółka Akcyjna keeps more of each sale as profit: 44.8% against 25.7%.
- SNT.WA
Which is growing its sales faster?
Synektik Spółka Akcyjna is growing its sales faster: +89.50% over the past year, against +22.50%.
- SNT.WA
Which has borrowed less?
Synektik Spółka Akcyjna has borrowed less: its debt is 19.4% of what its shareholders own, against 30.8% for UCB.
- UCB.BR
Which costs less for the profit it is expected to make?
UCB costs less for the profit it is expected to make: 18.7× its forward earnings, against 25.9×.
- SNT.WA
Which pays more in dividends?
Synektik Spółka Akcyjna pays more back in dividends for what a share costs: 3.40% a year, against 0.51%.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- UCB.BR
Which is in the stronger price trend?
UCB's price is in the stronger trend: 17.2% above its 200-day average, against 3.1% below.
What each company does
SNT.WASynektik Spółka Akcyjna
Synektik Spółka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland.
UCB.BRUCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
Reports results on 25 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.